Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

11.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-guided CRISPR screening reveals therapeutic targets in psoriasis.

Nature communications·2026
Same author

Stable Chelation of Zr-89 and Ac-225 with Dual Size-Selective Macrocyclic py<sub>2</sub>-macrodipa for <sup>225</sup>Ac/<sup>89</sup>Zr Paired Theranostics.

Inorganic chemistry·2026
Same author

Integrating Transcription Factors with Electrochemical Pendulum Bioanalysis for Hormone Detection.

Journal of the American Chemical Society·2026
Same author

Correction to "Size-Adaptive Macrocyclic Coordination of <sup>203</sup>Pb, <sup>207</sup>Bi, and <sup>133</sup>Ba by py-Macrodipa and py<sub>2</sub>-Macrodipa".

Inorganic chemistry·2026
Same author

Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets.

Nature communications·2026
Same author

Photoreactivity of Ru<sup>2+</sup> Polypyridyl Complexes Bearing the H<sub>2</sub>S-Releasing Compound GYY4137.

Inorganic chemistry·2026

Related Experiment Video

Updated: May 6, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.0K

Targeting mitochondrial DNA with a platinum-based anticancer agent.

Simon P Wisnovsky1, Justin J Wilson, Robert J Radford

  • 1Department of Biochemistry, Faculty of Medicine, University of Toronto, Toronto, ON M5S1A8, Canada.

Chemistry & Biology
|November 5, 2013
PubMed
Summary

Researchers delivered a cisplatin analog (mtPt) to human cell mitochondria using a targeted peptide. This demonstrates that damaging mitochondrial DNA is sufficient for platinum-based chemotherapy, bypassing nuclear DNA.

More Related Videos

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.6K
An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

6.4K

Related Experiment Videos

Last Updated: May 6, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.0K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.6K
An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

6.4K

Area of Science:

  • Mitochondrial biology
  • Cancer chemotherapy
  • Drug delivery

Background:

  • Cisplatin is a widely used platinum-based anticancer drug.
  • Current chemotherapy often causes severe side effects due to damage to nuclear DNA.
  • Targeting specific cellular organelles offers a potential strategy to improve drug efficacy and reduce toxicity.

Purpose of the Study:

  • To investigate the efficacy of delivering a platinum-based drug analog to mitochondria.
  • To determine if mitochondrial DNA (mtDNA) damage is sufficient to induce cancer cell death.
  • To explore the effects of organelle-specific drug delivery in cancer therapy.

Main Methods:

  • Synthesis of a cisplatin analog (mtPt) conjugated to a mitochondria-targeting peptide.
  • Treatment of human cells with the targeted mtPt.
  • Assessment of apoptosis induction and DNA damage in both nuclear and mitochondrial compartments.

Main Results:

  • The mtPt analog was successfully delivered to the mitochondria of human cells.
  • mtPt treatment induced apoptosis in cancer cells.
  • Apoptosis was observed without significant damage to nuclear DNA, but with evidence of mtDNA damage.

Conclusions:

  • Mitochondrial DNA damage is sufficient to mediate the activity of platinum-based chemotherapeutics.
  • Targeted delivery of anticancer drugs to mitochondria is a feasible strategy.
  • This approach may lead to novel cancer therapies with reduced systemic toxicity.